• 西安醫(yī)科大學(xué)第一臨床醫(yī)學(xué)院(西安710061);

引用本文： 石景森,秦興雷. CA19-9在膽囊癌診斷中的價(jià)值. 中國(guó)普外基礎(chǔ)與臨床雜志, 1997, 4(2): 110-111. doi: 復(fù)制

1. Scott JR,Carcinoma of the gallbladder.Surg Clin N Am,1990;70(6):1419.
2. Dearetxabalax.早期膽囊癌的手術(shù)所見(jiàn).國(guó)外醫(yī)學(xué)外科學(xué)分冊(cè),1990;17(4):236.
3. 石景森.膽囊癌的外科診治.肝膽胰脾外科雜志,1996;2(3):132.
4. Koporwski H,Steplewski Z,Mitchei K.Colon-rectal carcionma antigendetected by hybridoma antibodies.Somatic Cell Genetics,1979;5:957.
5. Koporwski H,Steplewski Z,Mitchei K.Specific antigen in serum of patients with colon carcinoma.Science,1981;212:53.
6. Del Villano BC.Radioimmunological assay for monoclonal antibydy-defined tumormarker CA19-9.Clin Chem,1983;29:549.
7. Ohshic G,Monahe T,Watamobe Y,et al.Comparative studies of DU-PAN-2,CEA,and CA19-9 in the serum and bile of patients with pancreatic and billiary tract disease:evaluations of the influence of obstructive jaundice.Am J Gastroenterol.1990;85(10):1370.
8. Albert MB,Steinberg WM.Elevated serum levels of tumor marker CA19-9 in acute cholangitis.Dig Dis Sci,1988;33:1223.
9. Hoglund C,Roberts PJ,Kuusela P,et al.Evaluation of CA19-9 as an serum tumor marker in pancreatic cancer.Br J Cancer,1986;53(2):197.
10. 陸雪龍,王百正,時(shí)紅珍.CA19-9RIA的臨床觀察，放射免疫學(xué)雜志,1992;5(4):222.
11. Berotta.Serum CA19-9 in the post surgical follow-up of patients with pancreatic cancer.Cancer,1987;60:2426.
12. Ker CG,Chen JS,Lee KT,et al.Assessment of serum and bile levels of CA19-9 and CA125 in cholangitis and bile duct carcinoma.J Gastroenterol Hepatol,1991;6(5):505.
13. 許昌泰,潘伯榮.腫瘤標(biāo)記CA19-9的臨床研究.日本醫(yī)學(xué)介紹,1990；11(2):93.
  1. 1. Scott JR,Carcinoma of the gallbladder.Surg Clin N Am,1990;70(6):1419.
  2. 2. Dearetxabalax.早期膽囊癌的手術(shù)所見(jiàn).國(guó)外醫(yī)學(xué)外科學(xué)分冊(cè),1990;17(4):236.
  3. 3. 石景森.膽囊癌的外科診治.肝膽胰脾外科雜志,1996;2(3):132.
  4. 4. Koporwski H,Steplewski Z,Mitchei K.Colon-rectal carcionma antigendetected by hybridoma antibodies.Somatic Cell Genetics,1979;5:957.
  5. 5. Koporwski H,Steplewski Z,Mitchei K.Specific antigen in serum of patients with colon carcinoma.Science,1981;212:53.
  6. 6. Del Villano BC.Radioimmunological assay for monoclonal antibydy-defined tumormarker CA19-9.Clin Chem,1983;29:549.
  7. 7. Ohshic G,Monahe T,Watamobe Y,et al.Comparative studies of DU-PAN-2,CEA,and CA19-9 in the serum and bile of patients with pancreatic and billiary tract disease:evaluations of the influence of obstructive jaundice.Am J Gastroenterol.1990;85(10):1370.
  8. 8. Albert MB,Steinberg WM.Elevated serum levels of tumor marker CA19-9 in acute cholangitis.Dig Dis Sci,1988;33:1223.
  9. 9. Hoglund C,Roberts PJ,Kuusela P,et al.Evaluation of CA19-9 as an serum tumor marker in pancreatic cancer.Br J Cancer,1986;53(2):197.
  10. 10. 陸雪龍,王百正,時(shí)紅珍.CA19-9RIA的臨床觀察，放射免疫學(xué)雜志,1992;5(4):222.
  11. 11. Berotta.Serum CA19-9 in the post surgical follow-up of patients with pancreatic cancer.Cancer,1987;60:2426.
  12. 12. Ker CG,Chen JS,Lee KT,et al.Assessment of serum and bile levels of CA19-9 and CA125 in cholangitis and bile duct carcinoma.J Gastroenterol Hepatol,1991;6(5):505.
  13. 13. 許昌泰,潘伯榮.腫瘤標(biāo)記CA19-9的臨床研究.日本醫(yī)學(xué)介紹,1990；11(2):93.